Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company’s web site at www.adherex.com.
- 17 years ago
QualityStocks
Adherex Technologies, Inc. (AMEX: ADH)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – BluSky AI Inc. (BSAI) Focused on Scalability in the Era of Artificial Intelligence
BluSky AI (OTC: BSAI) was featured in a recent article that discussed its strategic moves in…
-
QualityStocksNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Advancing Louisiana SMC to Play Pivotal Role in Critical Mineral Supply Chain
Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Releases New Datavault Insights Highlighting Execution, Growth and Global Momentum
Datavault AI (NASDAQ: DVLT) released a new Datavault Insights piece detailing the company’s ability to…